Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Buse

Showing results (81-90 of 457) with videos related to

Pageof 46
Sort By:
Diabetes Care|August 25, 2023
Felicia Hill-Briggs: A Tireless Worker for Better Outcomes and Social Justice in DiabetesCheryl A M Anderson, Stephanie L Fitzpatrick, John B Buse, et al.
Diabetes Care|October 21, 2017
Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular OutcomesMatthew J Crowley, John W Williams, Andrzej S Kosinski, et al.
Diabetes Care|May 20, 2026
Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265Johannes F E Mann, Ole Kleist Jeppesen, Nicolas Belmar, et al.
Diabetes Technology & Therapeutics|June 28, 2003
Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic markerJohn B Buse, Jennifer L R Freeman, Steven V Edelman, et al.
Diabetes Care|August 11, 2019
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized TrialMichael A Nauck, Marie Louise Muus Ghorbani, Eskil Kreiner, et al.
Journal of Dental Education|March 4, 2011
North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional educationJonathan B Owens, Rebecca S Wilder, Janet H Southerland, et al.
Diabetes|April 24, 2025
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its LongevitySteven E Kahn, Cheryl A M Anderson, John B Buse, et al.
Diabetes Care|April 24, 2025
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its LongevitySteven E Kahn, Cheryl A M Anderson, John B Buse, et al.
Science Translational Medicine|January 18, 2019
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activatorAdrian Vella, Jennifer L R Freeman, Imogene Dunn, et al.
Diabetes Care|April 19, 2015
The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trialJames M Hempe, Shuqian Liu, Leann Myers, et al.
Pageof 46

Showing results (81-90 of 457) with videos related to

Sort By:
Pageof 46
Diabetes Care|August 25, 2023
Felicia Hill-Briggs: A Tireless Worker for Better Outcomes and Social Justice in DiabetesCheryl A M Anderson, Stephanie L Fitzpatrick, John B Buse, et al.
Diabetes Care|October 21, 2017
Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular OutcomesMatthew J Crowley, John W Williams, Andrzej S Kosinski, et al.
Diabetes Care|May 20, 2026
Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265Johannes F E Mann, Ole Kleist Jeppesen, Nicolas Belmar, et al.
Diabetes Technology & Therapeutics|June 28, 2003
Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic markerJohn B Buse, Jennifer L R Freeman, Steven V Edelman, et al.
Diabetes Care|August 11, 2019
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized TrialMichael A Nauck, Marie Louise Muus Ghorbani, Eskil Kreiner, et al.
Journal of Dental Education|March 4, 2011
North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional educationJonathan B Owens, Rebecca S Wilder, Janet H Southerland, et al.
Diabetes|April 24, 2025
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its LongevitySteven E Kahn, Cheryl A M Anderson, John B Buse, et al.
Diabetes Care|April 24, 2025
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its LongevitySteven E Kahn, Cheryl A M Anderson, John B Buse, et al.
Science Translational Medicine|January 18, 2019
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activatorAdrian Vella, Jennifer L R Freeman, Imogene Dunn, et al.
Diabetes Care|April 19, 2015
The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trialJames M Hempe, Shuqian Liu, Leann Myers, et al.
Pageof 46